PepGen Reports Progress in Duchenne Treatment Trials
PremiumCompany AnnouncementsPepGen Reports Progress in Duchenne Treatment Trials
2M ago
PepGen reports ‘positive’ data from low-dose cohort of PGN-EDO51
Premium
The Fly
PepGen reports ‘positive’ data from low-dose cohort of PGN-EDO51
2M ago
PepGen files $250M mixed securities shelf
Premium
The Fly
PepGen files $250M mixed securities shelf
3M ago
PepGen to Participate in Upcoming Investor Conferences
PremiumPress ReleasesPepGen to Participate in Upcoming Investor Conferences
6M ago
PepGen receives Orphan Drug, Rare Pediatric Disease designations for PGN-EDO51
Premium
The Fly
PepGen receives Orphan Drug, Rare Pediatric Disease designations for PGN-EDO51
6M ago
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
Premium
Press Releases
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
6M ago
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
PremiumPress ReleasesPepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
7M ago
PepGen announces clearance of CTA by U.K. MHRA to begin CONNECT2-EDO51
Premium
The Fly
PepGen announces clearance of CTA by U.K. MHRA to begin CONNECT2-EDO51
7M ago
PepGen Earns FDA Fast Track Status for Myotonic Dystrophy Drug
Premium
Company Announcements
PepGen Earns FDA Fast Track Status for Myotonic Dystrophy Drug
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100